BORTEZOMIB MAINTENANCE TREATMENT IN PATIENTS WITH MULTIPLE MYELOMA-A SINGLE CENTER EXPERIENCE
(Abstract release date: 05/19/16)
EHA Library. Micheva I. 06/09/16; 134885; PB1985
Ilina Micheva
Contributions
Contributions
Abstract
Abstract: PB1985
Type: Publication Only
Background
The long-term maintenance therapy in multiple myeloma (MM) after definitive therapy may prolong remission and delay relapse. Bortezomib has been used as post-autologous stem-cell transplantation (ASCT) consolidation therapy. Other trials have investigated Bortezomib maintenance for ASCT patients, and for those who are ASCT ineligible.
Aims
To define the role of Bortezomib maintenance therapy (MT) in patients with MM after achieving complete response (CR) or very good partial response (VGPR).
Methods
37 patients with newly diagnosed symptomatic MM with CR or VGPR after Bortezomib based induction regiments were included in the analysis. 23 patients received MT with Bortezomib 1.3 mg/m2 once every 2 weeks. 14 patients remained on follow up until progression.
Results
19 of the patients were men and 18 women with median of age 64,2 years. 11 cases were with IgA myeloma, 20 with IgG, and 6 with light chain myeloma. According to ISS 10 patients were in stage I, 7 in stage II, and 20 in stage III. CR was achieved in 13 (56,5%) of the patients in MT group and in 6 (42,8%) in the group on follow up. Total of 14 patients underwent ASCT - 10 (43,4%) from the patients on MT and 4 (28,5%) on follow up. After a median follow up of 31.8 months (range, 10-65 months) none of the patients on Bortezomibe MT progressed. In contrast, in the patients group on follow up, 12 from 14 patients progressed within median time of 24,17 months (range, 7-60 months). No correlation was found between the progression and myeloma type, ISS stage, type of response and ASCT.
Conclusion
Our results reveal undoubtedly the impotence of Bortesomib maintenance in patients achieved CR or VGPR.
Session topic: E-poster
Keyword(s): Bortezomib, Maintenance, Myeloma
Type: Publication Only
Background
The long-term maintenance therapy in multiple myeloma (MM) after definitive therapy may prolong remission and delay relapse. Bortezomib has been used as post-autologous stem-cell transplantation (ASCT) consolidation therapy. Other trials have investigated Bortezomib maintenance for ASCT patients, and for those who are ASCT ineligible.
Aims
To define the role of Bortezomib maintenance therapy (MT) in patients with MM after achieving complete response (CR) or very good partial response (VGPR).
Methods
37 patients with newly diagnosed symptomatic MM with CR or VGPR after Bortezomib based induction regiments were included in the analysis. 23 patients received MT with Bortezomib 1.3 mg/m2 once every 2 weeks. 14 patients remained on follow up until progression.
Results
19 of the patients were men and 18 women with median of age 64,2 years. 11 cases were with IgA myeloma, 20 with IgG, and 6 with light chain myeloma. According to ISS 10 patients were in stage I, 7 in stage II, and 20 in stage III. CR was achieved in 13 (56,5%) of the patients in MT group and in 6 (42,8%) in the group on follow up. Total of 14 patients underwent ASCT - 10 (43,4%) from the patients on MT and 4 (28,5%) on follow up. After a median follow up of 31.8 months (range, 10-65 months) none of the patients on Bortezomibe MT progressed. In contrast, in the patients group on follow up, 12 from 14 patients progressed within median time of 24,17 months (range, 7-60 months). No correlation was found between the progression and myeloma type, ISS stage, type of response and ASCT.
Conclusion
Our results reveal undoubtedly the impotence of Bortesomib maintenance in patients achieved CR or VGPR.
Session topic: E-poster
Keyword(s): Bortezomib, Maintenance, Myeloma
Abstract: PB1985
Type: Publication Only
Background
The long-term maintenance therapy in multiple myeloma (MM) after definitive therapy may prolong remission and delay relapse. Bortezomib has been used as post-autologous stem-cell transplantation (ASCT) consolidation therapy. Other trials have investigated Bortezomib maintenance for ASCT patients, and for those who are ASCT ineligible.
Aims
To define the role of Bortezomib maintenance therapy (MT) in patients with MM after achieving complete response (CR) or very good partial response (VGPR).
Methods
37 patients with newly diagnosed symptomatic MM with CR or VGPR after Bortezomib based induction regiments were included in the analysis. 23 patients received MT with Bortezomib 1.3 mg/m2 once every 2 weeks. 14 patients remained on follow up until progression.
Results
19 of the patients were men and 18 women with median of age 64,2 years. 11 cases were with IgA myeloma, 20 with IgG, and 6 with light chain myeloma. According to ISS 10 patients were in stage I, 7 in stage II, and 20 in stage III. CR was achieved in 13 (56,5%) of the patients in MT group and in 6 (42,8%) in the group on follow up. Total of 14 patients underwent ASCT - 10 (43,4%) from the patients on MT and 4 (28,5%) on follow up. After a median follow up of 31.8 months (range, 10-65 months) none of the patients on Bortezomibe MT progressed. In contrast, in the patients group on follow up, 12 from 14 patients progressed within median time of 24,17 months (range, 7-60 months). No correlation was found between the progression and myeloma type, ISS stage, type of response and ASCT.
Conclusion
Our results reveal undoubtedly the impotence of Bortesomib maintenance in patients achieved CR or VGPR.
Session topic: E-poster
Keyword(s): Bortezomib, Maintenance, Myeloma
Type: Publication Only
Background
The long-term maintenance therapy in multiple myeloma (MM) after definitive therapy may prolong remission and delay relapse. Bortezomib has been used as post-autologous stem-cell transplantation (ASCT) consolidation therapy. Other trials have investigated Bortezomib maintenance for ASCT patients, and for those who are ASCT ineligible.
Aims
To define the role of Bortezomib maintenance therapy (MT) in patients with MM after achieving complete response (CR) or very good partial response (VGPR).
Methods
37 patients with newly diagnosed symptomatic MM with CR or VGPR after Bortezomib based induction regiments were included in the analysis. 23 patients received MT with Bortezomib 1.3 mg/m2 once every 2 weeks. 14 patients remained on follow up until progression.
Results
19 of the patients were men and 18 women with median of age 64,2 years. 11 cases were with IgA myeloma, 20 with IgG, and 6 with light chain myeloma. According to ISS 10 patients were in stage I, 7 in stage II, and 20 in stage III. CR was achieved in 13 (56,5%) of the patients in MT group and in 6 (42,8%) in the group on follow up. Total of 14 patients underwent ASCT - 10 (43,4%) from the patients on MT and 4 (28,5%) on follow up. After a median follow up of 31.8 months (range, 10-65 months) none of the patients on Bortezomibe MT progressed. In contrast, in the patients group on follow up, 12 from 14 patients progressed within median time of 24,17 months (range, 7-60 months). No correlation was found between the progression and myeloma type, ISS stage, type of response and ASCT.
Conclusion
Our results reveal undoubtedly the impotence of Bortesomib maintenance in patients achieved CR or VGPR.
Session topic: E-poster
Keyword(s): Bortezomib, Maintenance, Myeloma
{{ help_message }}
{{filter}}